Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PROPECIA

« Back to Dashboard
Propecia is a drug marketed by Merck and is included in one NDA. It is available from three suppliers.

The generic ingredient in PROPECIA is finasteride. There are fourteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the finasteride profile page.

Summary for Tradename: PROPECIA

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list6

Pharmacology for Tradename: PROPECIA

Clinical Trials for: PROPECIA

Bioequivalence Study of Dr. Reddy's Laboratories Limited, Finasteride Tablets 1 mg Under Fasting Condition
Status: Completed Condition: Healthy

Bioequivalence Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg Under Fed Condition
Status: Completed Condition: Healthy

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Finasteride for Chronic Central Serous Chorioretinopathy
Status: Terminated Condition: Retinal Disease

A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy
Status: Completed Condition: Enlarged Prostate

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy
Status: Completed Condition: Retinal Disease

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions
Status: Completed Condition: Healthy

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions
Status: Completed Condition: Healthy

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)
Status: Terminated Condition: Benign Prostatic Hyperplasia

H-36731: Finasteride in Management of Elevated Red Blood Cells
Status: Not yet recruiting Condition: ERYTHROCYTOSIS

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
PROPECIA
finasteride
TABLET;ORAL020788-001Dec 19, 1997RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROPECIA

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
PROPECIA
finasteride
TABLET;ORAL020788-001Dec 19, 19974,377,584<disabled>
Merck
PROPECIA
finasteride
TABLET;ORAL020788-001Dec 19, 19975,886,184<disabled>
Merck
PROPECIA
finasteride
TABLET;ORAL020788-001Dec 19, 19974,760,071<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc